Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | acetylcholinesterase | 0.0082 | 0.3607 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0082 | 0.3607 | 0.3607 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0111 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0082 | 0.3607 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0082 | 0.3607 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0082 | 0.3607 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0111 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.3607 | 0.3607 |
Echinococcus granulosus | carboxylesterase 5A | 0.0082 | 0.3607 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0082 | 0.3607 | 0.3607 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0082 | 0.3607 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0082 | 0.3607 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.0082 | 0.3607 | 0.3607 |
Brugia malayi | Carboxylesterase family protein | 0.0082 | 0.3607 | 0.3607 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.3607 | 0.3607 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
DOSE (functional) | mg kg-1 | Compound was evaluated for reversal of scopalamine-induced memory imparement in mice when administered subcutaneously; Not active (1-10 mg/kg) | ChEMBL. | No reference |
Dose (functional) | NA 0 mg kg-1 | Compound was evaluated for reversal of scopalamine-induced memory imparement in mice when administered subcutaneously; Not active (1-10 mg/kg) | ChEMBL. | No reference |
IC50 (binding) | = 62.1 uM | Inhibition of acetylcholinesterase | ChEMBL. | No reference |
IC50 (binding) | = 62.1 uM | Inhibition of acetylcholinesterase | ChEMBL. | No reference |
LD50 (ADMET) | > 80 mg kg-1 | Acute toxicity of the compound in mice when administered subcutaneously | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.